Literature DB >> 25246228

Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system.

Melanie M Hoefer1, Ana B Sanchez2, Ricky Maung3, Cyrus M de Rozieres4, Irene C Catalan5, Cari C Dowling6, Victoria E Thaney7, Juan Piña-Crespo8, Dongxian Zhang9, Amanda J Roberts10, Marcus Kaul11.   

Abstract

Methamphetamine (METH) abuse is frequent in individuals infected with human immunodeficiency virus type-1 (HIV-1) and is suspected to aggravate HIV-associated neurocognitive disorders (HAND). METH is a psychostimulant that compromises several neurotransmitter systems and HIV proteins trigger neuronal injury but the combined effects of viral infection and METH abuse are incompletely understood. In this study we treated transgenic mice expressing the HIV envelope protein gp120 in the brain (HIV-1 gp120tg) at 3-4 months of age with an escalating-dose, multiple-binge METH regimen. The long-term effects were analyzed after 6-7 months of drug abstinence employing behavioral tests and analysis of neuropathology, electrophysiology and gene expression. Behavioral testing showed that both HIV-1 gp120tg and WT animals treated with METH displayed impaired learning and memory. Neuropathological analysis revealed that METH similar to HIV-1 gp120 caused a significant loss of neuronal dendrites and pre-synaptic terminals in hippocampus and cerebral cortex of WT animals. Electrophysiological studies in hippocampal slices showed that METH exposed HIV-1 gp120tg animals displayed reduced post-tetanic potentiation, whereas both gp120 expression and METH lead to reduced long-term potentiation. A quantitative reverse transcription-polymerase chain reaction array showed that gp120 expression, METH and their combination each caused a significant dysregulation of specific components of GABAergic and glutamatergic neurotransmission systems, providing a possible mechanism for synaptic dysfunction and behavioral impairment. In conclusion, both HIV-1 gp120 and METH caused lasting behavioral impairment in association with neuropathology and altered gene expression. However, combined METH exposure and HIV-1 gp120 expression resulted in the most pronounced, long lasting pre- and post-synaptic alterations coinciding with impaired learning and memory.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavior; Electrophysiology; Gene expression; HIV-1 gp120; Methamphetamine; NeuroAIDS; Neuropathology; Transgenic animal model

Mesh:

Substances:

Year:  2014        PMID: 25246228      PMCID: PMC4370186          DOI: 10.1016/j.expneurol.2014.09.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  102 in total

1.  Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6.

Authors:  B Ladenheim; I N Krasnova; X Deng; J M Oyler; A Polettini; T H Moran; M A Huestis; J L Cadet
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Post-tetanic potentiation.

Authors:  J R HUGHES
Journal:  Physiol Rev       Date:  1958-01       Impact factor: 37.312

Review 3.  A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.

Authors:  Stephanie D Kraft-Terry; Shilpa J Buch; Howard S Fox; Howard E Gendelman
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

4.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor.

Authors:  B Johansson; L Halldner; T V Dunwiddie; S A Masino; W Poelchen; L Giménez-Llort; R M Escorihuela; A Fernández-Teruel; Z Wiesenfeld-Hallin; X J Xu; A Hårdemark; C Betsholtz; E Herlenius; B B Fredholm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

5.  Purification and characterization of P400 protein, a glycoprotein characteristic of Purkinje cell, from mouse cerebellum.

Authors:  N Maeda; M Niinobe; K Nakahira; K Mikoshiba
Journal:  J Neurochem       Date:  1988-12       Impact factor: 5.372

Review 6.  Biochemical and electrophysiological characteristics of mammalian GABA receptors.

Authors:  S J Enna; J P Gallagher
Journal:  Int Rev Neurobiol       Date:  1983       Impact factor: 3.230

7.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

8.  Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection.

Authors:  Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; Robert K Heaton; Igor Grant
Journal:  AIDS Behav       Date:  2006-03

9.  Alteration of Methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120.

Authors:  Amanda J Roberts; Ricky Maung; Natalia E Sejbuk; Christopher Ake; Marcus Kaul
Journal:  J Neurosci Methods       Date:  2009-11-13       Impact factor: 2.390

10.  Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain.

Authors:  Govinder Flora; Yong Woo Lee; Avindra Nath; Bernhard Hennig; William Maragos; Michal Toborek
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

View more
  29 in total

Review 1.  Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.

Authors:  Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

2.  HIV-1 Glycoprotein 120 Enhancement of N-Methyl-D-Aspartate NMDA Receptor-Mediated Excitatory Postsynaptic Currents: Implications for HIV-1-Associated Neural Injury.

Authors:  Yan Zhou; Jianuo Liu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-22       Impact factor: 4.147

Review 3.  Role of microglia in methamphetamine-induced neurotoxicity.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-06-15

4.  Methamphetamine potentiates HIV-1gp120-induced microglial neurotoxic activity by enhancing microglial outward K+ current.

Authors:  Jianuo Liu; Enquan Xu; Guihua Tu; Han Liu; Jiangtao Luo; Huangui Xiong
Journal:  Mol Cell Neurosci       Date:  2017-05-25       Impact factor: 4.314

5.  Methamphetamine augment HIV-1 Tat mediated memory deficits by altering the expression of synaptic proteins and neurotrophic factors.

Authors:  Anantha Ram Nookala; Daniel C Schwartz; Nitish S Chaudhari; Alexy Glazyrin; Edward B Stephens; Nancy E J Berman; Anil Kumar
Journal:  Brain Behav Immun       Date:  2018-05-02       Impact factor: 7.217

Review 6.  Role of Autophagy in HIV Pathogenesis and Drug Abuse.

Authors:  Lu Cao; Alexey Glazyrin; Santosh Kumar; Anil Kumar
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults.

Authors:  Virawudh Soontornniyomkij; Anya Umlauf; Benchawanna Soontornniyomkij; Isabella B Batki; David J Moore; Eliezer Masliah; Cristian L Achim
Journal:  J Neurovirol       Date:  2016-04-20       Impact factor: 2.643

Review 8.  Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior.

Authors:  Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-15       Impact factor: 4.147

Review 9.  Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research.

Authors:  Victoria E Thaney; Ana B Sanchez; Jerel A Fields; Arpi Minassian; Jared W Young; Ricky Maung; Marcus Kaul
Journal:  J Neurovirol       Date:  2017-10-26       Impact factor: 2.643

10.  Phosphorylated CCAAT/Enhancer Binding Protein β Contributes to Rat HIV-Related Neuropathic Pain: In Vitro and In Vivo Studies.

Authors:  Hyun Yi; Shue Liu; Yuta Kashiwagi; Daigo Ikegami; Wan Huang; Hirotsugu Kanda; Takafumi Iida; Ching-Hang Liu; Keiya Takahashi; David A Lubarsky; Shuanglin Hao
Journal:  J Neurosci       Date:  2017-12-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.